AZ5104 is a demethylated metabolite of AZD-9291. AZ-5104 was identified to exhibit 5-fold potency compared to AZD-9291, which is currently in clinical trial. AZ5104 is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively.
EGFR Inhibitors Related Products:
PD153035; Nazartinib; AZD3759; Erlotinib; CL-387785; ARRY-380 analog; MTX-211; Osimertinib; Osimertinib mesylate; Olmutinib; Afatinib Dimaleate; Rociletinib; EGFR-IN-7